From Insight to Impact: The Strategic Role of Biomarkers in Drug Discovery and Clinical Trials
Every decision in drug development carries weight.
The right biomarker insights can make those decisions more confident and data-driven.
In this white paper, experts from AstraZeneca, Johnson & Johnson, and Takeda Pharmaceuticals share how biomarker strategies are helping R&D teams strengthen target selection, accelerate timelines, reduce development risk, and improve clinical trial outcomes.
Download the white paper and watch the panel discussion to discover how biomarker insights are advancing drug development through better-informed, evidence-based decisions.